Company Overview
Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women's Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDerm, a human acellular dermal matrix used in soft tissue reconstruction. It also offers ProxiCor for cardiac tissue repair for use as an intracardiac patch for repairs, such as atrial and ventricular septal defects and suture-line buttressing, and pledgets, as well as for pericardial closure to reconstruct the pericardium after heart surgery. In addition, the company provides Tyke, a thinner pliable matrix for the repair of pericardial structures for neonates and infants; as an epicardial for damaged or repaired cardiac structures; and as a patch material for cardiac defects, as well as VasCure, a patch material to repair or reconstruct the peripheral vasculature. The company sells its products directly to hospitals and other healthcare facilities through independent sales agents. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Gaithersburg, Maryland.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.28.
Recent Developments
- Dec 2025 Revenue of $12.29M (-15.0% YoY); net profit $53.38M.
- Trailing 12 Months Year-on-year growth — revenue -11.6%.
- 5-Year Trend Long-term compounding — revenue CAGR -18.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -18.80% |
| 1 Year: | -11.60% |
Stock Price Performance
| 1 Year: | -61.57% |
| 6 Months: | -29.06% |
| 3 Months: | -16.16% |
| 1 Month: | -2.35% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)40.63 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -18.8% CAGR over 5 years.
- Trading 65.4% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ELUT Elutia Inc. PHARMA | 0.83 | -1.32 | $36.76M | 0.00% | -72.32% | - | -18.80% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 11.14M | 9.86M | 8.58M | 11.77M | 12.88M | 12.16M | 11.48M | 11.49M | 12.64M | 5.85M | 6.39M | 6.35M | 6.13M | 6.69M | 6.29M | 3.66M | 2.95M | 6.26M | 3.32M | 3.11M |
| Gross Profit | 5.54M | 5.21M | 3.78M | 5.54M | 6.33M | 5.61M | 3.69M | 4.28M | 4.90M | 2.94M | 3.37M | 2.71M | 2.84M | 2.84M | 2.80M | 1.79M | 1.38M | 3.06M | 1.85M | 1.80M |
| Operating Income | -1.85M | -3.18M | -3.76M | -2.69M | -3.70M | -4.59M | -6.98M | -6.92M | -8.18M | -8.97M | -8.34M | -6.31M | -7.37M | -8.48M | -8.51M | -9.18M | -6.78M | -9.88M | -5.21M | -6.35M |
| Net Income | -3.10M | -4.56M | -5.18M | -6.73M | -5.07M | -2.38M | -8.32M | -8.15M | -9.40M | -9.91M | -7.97M | -10.62M | -9.75M | -17.99M | -28.18M | 1.29M | -3.93M | -9.61M | -3.87M | -7.47M |
| Diluted EPS | - | - | -7.99 | -15.79 | -0.50 | -0.23 | -0.81 | -0.60 | -0.69 | -0.73 | -0.49 | -0.65 | -0.57 | -0.75 | -1.13 | -0.33 | -0.21 | -0.26 | -0.19 | -0.17 |
| R&D Expense | 507.00K | 1.31M | 1.41M | 1.26M | 1.72M | 1.88M | 2.29M | 2.27M | 2.62M | 1.72M | 1.59M | 869.00K | 557.00K | 1.17M | 1.00M | 702.00K | 871.00K | 1.46M | 1.09M | 1.97M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 42.90M | 42.68M | 47.39M | 23.85M | 24.75M | 14.47M | 12.29M |
| Gross Profit | 19.77M | 20.56M | 19.02M | 11.64M | 11.05M | 6.71M | 6.60M |
| Operating Income | -8.41M | -13.60M | -23.03M | -35.19M | -30.53M | -30.71M | -26.91M |
| Net Income | -11.94M | -21.82M | -24.83M | -32.90M | -37.66M | -53.95M | 53.38M |
| Diluted EPS | - | -8.88 | -2.38 | -2.38 | -2.07 | -1.86 | 0.87 |
| R&D Expense | 2.40M | 5.95M | 9.27M | 7.73M | 4.40M | 3.00M | 4.16M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 44.77M | 82.81M | 67.17M | 68.84M | 43.43M | 36.13M | 62.35M |
| Total Equity | -43.41M | -55.11M | 20.83M | 13.52M | -5.03M | -38.60M | -46.26M | 27.67M |
| Cash & Equivalents | - | 2.48M | 39.15M | 30.39M | 16.99M | 19.28M | 13.24M | 36.35M |
| Long Term Debt | - | 19.61M | 17.81M | 10.41M | 24.26M | 20.36M | 22.60M | - |
| Total Liabilities | - | 55.43M | 61.98M | 53.65M | 73.87M | 82.03M | 82.39M | 34.68M |
| Current Liabilities | - | 18.27M | 26.78M | 26.00M | 42.62M | 43.04M | 37.80M | 25.14M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -7.22M | -13.63M | -15.45M | -21.43M | -21.76M | -22.66M | -44.81M |
| Investing Cash Flow | -577.00K | -640.00K | -369.00K | -540.00K | 14.21M | -474.00K | 78.56M |
| Financing Cash Flow | 7.98M | 51.21M | 6.71M | 8.54M | 9.84M | 17.09M | -10.64M |
| Capital Expenditure | -577.00K | -640.00K | -369.00K | -540.00K | -346.00K | -654.00K | -1.88M |
| Free Cash Flow | -7.80M | -14.27M | -15.81M | -21.97M | -22.11M | -23.31M | -46.69M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | 46.1% | 48.2% | 40.1% | 48.8% | 44.7% | 46.4% | 53.7% |
| Operating Margin % | -19.6% | -31.9% | -48.6% | -147.5% | -123.4% | -212.3% | -218.9% |
| Net Margin % | -27.8% | -51.1% | -52.4% | -137.9% | -152.2% | -372.9% | 434.2% |
| ROE % | 21.7% | -104.8% | -183.7% | 653.6% | 97.6% | 116.6% | 192.9% |
| ROCE % | -31.7% | -24.3% | -55.9% | -134.2% | -7,807.2% | 1,841.2% | -72.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Nantahala Capital Management, LLC | 7.19% | 3.18M | $2.71M |
| 2 | AIGH Capital Management LLC | 6.09% | 2.70M | $2.29M |
| 3 | Knollwood Investment Advisory, LLC | 5.77% | 2.56M | $2.17M |
| 4 | SilverArc Capital Management, LLC | 4.95% | 2.19M | $1.86M |
| 5 | Vanguard Capital Management LLC | 2.58% | 1.14M | $971.19K |
| 6 | Perkins Capital Management, Inc. | 1.57% | 694.09K | $589.98K |
| 7 | Geode Capital Management, LLC | 0.64% | 285.23K | $242.44K |
| 8 | Corient Private Wealth LP | 0.57% | 253.50K | $215.47K |
| 9 | Renaissance Technologies, LLC | 0.46% | 201.82K | $171.54K |
| 10 | Vanguard Fiduciary Trust Co | 0.39% | 172.45K | $146.58K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ELUT
Post-surgical infections will be discussed at Elutia's upcoming talks - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxPQzhvYW8wRUpXUGZzb3hsT1ktdDk4QTVMcHVsQTI1UzBnX1B2OFNuRlNpaFdHYWV4UmFyRGozY1VPTUhJTG1NOWpVZXQ3N2hVY3R2MnZGcWt2VmIyamcxOEVIRng5S3VPZl9CLXhiMlk3VTlXMFZyVFFWMGVVTThXVE9mWURKdDc2Y3ZDMn…
Elutia Inc. (ELUT) Stock Falls on Q2 2026 Earnings - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxPZkNraFFUT01ZOTlKZjl2MWU5MnlIaG9ucGZrUnlaTURuUVJGNGNuZi1ycktaYi1Lbk1zdnI4VWlOcThtSWtTY2lnN0syQWdEc1NqMWgzbUpHbjAyNlRFMG0wcExSOFdNUGo0cTB1MTRkZnhOZ285V0Itc2xHWEhZM0M5VTRXTGVhY0l5RW…
Elutia Inc. (NASDAQ: ELUT) Share Price, ELUT Stock News, ELUT Share Price & Updates - kalkine.com.au
<a href="https://news.google.com/rss/articles/CBMiVkFVX3lxTE9wcUNQcFExSTduRHBFQ3Rfc1psRWM1U0xfOXBaMTRpSVBxUlNIVVZIRlNNaWVUY01rcnFPZzd2SjhXNnJtci1lU01BSHFabjlXdDNLU0Rn?oc=5" target="_blank">Elutia Inc. (NASDAQ: ELUT) Share Price, ELUT Stock …
ELUT - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE1ITG9JUnpiamVuVjJOR0hKcnJRRWlTOExXQ1dWdldJd1pxWWpRS2ZySDNoeUNGUzQ4alRWaU5SRDJWd2d3b2c?oc=5" target="_blank">ELUT</a> <font color="#6f6f6f">Finviz</font>…
ELUT Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE9PYkxJRUlLMGZRVFlrdFlOZGVXNXZJeTVnTzN3NmxpS0o0U0xtRnlCNllFdkRDU3Q3amNzSGw0bGtxWWs4ZTZGX05JeURUb29IQ1l2SERKUTBEbmVDU3hTNkJRNWNyN1dSTGVPWF9ON1NiVGl6cGZ3cGpB?oc=5" target="_blank">ELU…
Earnings To Watch: Elutia Inc (ELUT) Q2 2026 -- GF Value Sees 6% Downside - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxPMi1xcUY0cFBfVkRUa0swRVNvTU4xQjRSR2FySENkMlZGaTdBMEw1aEFzbTBoWGxYZnVSTVpxbm8wTWdTMkEzR18yQVlnTUZYRjNOSVVYY3BncU5Ncmk3djJTaml5Ql8zRVVwVVlSSTl0UDVnVzV4YXdWSFZCbG5sR2hDNkhVdUtGUUk5TE…
ELUT — Frequently Asked Questions
What is the current share price of Elutia Inc. (ELUT)?
As of 2026-09-19 21:16 PDT, Elutia Inc. (ELUT) trades at $0.83 on NasdaqCM. Its 52-week range is $0.50 to $2.40.
What is the market capitalisation of ELUT?
Elutia Inc. (ELUT) has a market capitalisation of $36.76M on NasdaqCM.
What is the P/E ratio of ELUT?
ELUT trades at a trailing price-to-earnings (P/E) ratio of -1.32. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 2.25.
Is ELUT a good stock to buy?
This page provides a data-driven analysis of Elutia Inc. (ELUT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.